166 related articles for article (PubMed ID: 38241514)
1. Post Hoc Analysis of Lung Function Improvement and Patient-Reported Outcomes With Revefenacin in Adults With Moderate-to-Very Severe COPD and Comorbid Anxiety or Depression.
Yohannes AM; Iyer AS; Clay C; Cochran L; Chen X; Lombardi DA; Bhatt SP
Chronic Obstr Pulm Dis; 2024 Mar; 11(2):196-205. PubMed ID: 38241514
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis.
Donohue JF; Kerwin E; Barnes CN; Moran EJ; Haumann B; Crater GD
BMC Pulm Med; 2020 May; 20(1):134. PubMed ID: 32393215
[TBL] [Abstract][Full Text] [Related]
3. Improvements in health status with revefenacin, a once-daily, nebulized, long-acting muscarinic antagonist for chronic obstructive pulmonary disease.
Donohue JF; Ferguson GT; Ohar JA; Lombardi DA; Schneider RF; Johnson K
Respir Med; 2023 Mar; 208():107123. PubMed ID: 36681255
[TBL] [Abstract][Full Text] [Related]
4. Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies.
Hanania NA; Yohannes AM; Ozol-Godfrey A; Tocco M; Goodin T; Sharma S; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2021; 16():865-875. PubMed ID: 33833507
[TBL] [Abstract][Full Text] [Related]
5. Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD).
Donohue JF; Kerwin E; Sethi S; Haumann B; Pendyala S; Dean L; Barnes CN; Moran EJ; Crater G
Respir Res; 2019 Oct; 20(1):241. PubMed ID: 31666076
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials.
Sethi S; Donohue JF; Ferguson GT; Barnes CN; Crater GD
Ther Adv Respir Dis; 2020; 14():1753466620905278. PubMed ID: 32106777
[TBL] [Abstract][Full Text] [Related]
7. Improvements in Lung Function with Nebulized Revefenacin in the Treatment of Patients with Moderate to Very Severe COPD: Results from Two Replicate Phase III Clinical Trials.
Ferguson GT; Feldman G; Pudi KK; Barnes CN; Moran EJ; Haumann B; Pendyala S; Crater G
Chronic Obstr Pulm Dis; 2019 Apr; 6(2):154-165. PubMed ID: 30974049
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
[TBL] [Abstract][Full Text] [Related]
9. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease.
Pudi KK; Barnes CN; Moran EJ; Haumann B; Kerwin E
Respir Res; 2017 Nov; 18(1):182. PubMed ID: 29096627
[TBL] [Abstract][Full Text] [Related]
10. Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
Ni H; Moe S; Soe Z; Myint KT; Viswanathan KN
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011594. PubMed ID: 30536566
[TBL] [Abstract][Full Text] [Related]
11. Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease.
Donohue JF; Kerwin E; Sethi S; Haumann B; Pendyala S; Dean L; Barnes CN; Moran EJ; Crater G
Respir Med; 2019 Jul; 153():38-43. PubMed ID: 31150963
[TBL] [Abstract][Full Text] [Related]
12. Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD.
Donohue JF; Mahler DA; Sethi S
Int J Chron Obstruct Pulmon Dis; 2019; 14():2947-2958. PubMed ID: 31908443
[TBL] [Abstract][Full Text] [Related]
13. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
Maqsood U; Ho TN; Palmer K; Eccles FJ; Munavvar M; Wang R; Crossingham I; Evans DJ
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD012930. PubMed ID: 30839102
[TBL] [Abstract][Full Text] [Related]
14. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.
van Geffen WH; Tan DJ; Walters JA; Walters EH
Cochrane Database Syst Rev; 2023 Dec; 12(12):CD011600. PubMed ID: 38054551
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Revefenacin and Formoterol in Sequence and Combination via a Standard Jet Nebulizer in Patients with Chronic Obstructive Pulmonary Disease: A Phase 3b, Randomized, 42-Day Study.
Siler TM; Moran EJ; Barnes CN; Crater GD
Chronic Obstr Pulm Dis; 2020 Apr; 7(2):99-106. PubMed ID: 32324981
[TBL] [Abstract][Full Text] [Related]
16. Revefenacin, a once-daily, long-acting muscarinic antagonist, for nebulized maintenance therapy in patients with chronic obstructive pulmonary disease.
Hvisdas C
Am J Health Syst Pharm; 2021 Jun; 78(13):1184-1194. PubMed ID: 33821890
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of glycopyrrolate/eFlow
Kerwin E; Donohue JF; Goodin T; Tosiello R; Wheeler A; Ferguson GT
Respir Med; 2017 Nov; 132():238-250. PubMed ID: 28838685
[TBL] [Abstract][Full Text] [Related]
18. Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.
Ohar JA; Ozol-Godfrey A; Goodin T; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2020; 15():995-1004. PubMed ID: 32440111
[TBL] [Abstract][Full Text] [Related]
19. Emerging Treatments for COPD: Evidence to Date on Revefenacin.
Lal C; Khan A
COPD; 2020 Feb; 17(1):112-119. PubMed ID: 31833419
[TBL] [Abstract][Full Text] [Related]
20. Safety evaluation of revefenacin at the approved dose in patients with chronic obstructive pulmonary disease: A meta-analysis.
Liu B; Zan S; Luo W
Heart Lung; 2022; 52():52-60. PubMed ID: 34875569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]